Company intelligence / Profile preview

Biodesix

Boulder, Colorado, United Statesbiodesix.com ↗

Ownership: Public · BDSX
Development stage: Other

Overview

Biodesix has five Medicare-covered, non-invasive blood-based diagnostic tests for lung disease and lung cancer management. These include the Nodify Lung® strategy for nodule risk assessment and the IQLung™ strategy for treatment guidance in lung cancer. The company’s tests are used to expedite diagnosis and guide personalized treatment decisions with rapid turnaround times of 2–3 business days. Clinical adoption continues to grow rapidly, as evidenced by strong revenue growth[4][5][7].

Therapeutic areas: OncologyPulmonologyInfectious Diseases
Modalities: Genomic diagnosticsProteomic diagnosticsMultiomicsDroplet Digital PCR (ddPCR)Next Generation Sequencing (NGS)
Industry: Molecular Diagnostics

Partnerships

Bio-Rad Laboratories8 of the top 10 pharmaceutical companies

Financials

Market cap: $161.5M
Total revenue: $88.5M
Enterprise value: $205.5M

Beyond the preview

Go deeper on Biodesix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biodesix.